Clinical Trial Update: Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 safety study of paliperidone ER in geriatric patients with schizophrenia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Invega ER (paliperidone extended-release)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED